The global Lipid Nanoparticles Market was valued at US$ 789.0 million in 2022 and is expected to reach US$ 3.3 billion by 2033. Solid lipid nanoparticles, with around 64.8% of value share in 2022, dominated the market. The market is further projected to surge at a CAGR of 14.2% in the estimated period 2023 to 2033.
| Attributes | Key Insights |
|---|---|
| Lipid Nanoparticles Market Size (2022A) | US$ 789.0 million |
| Estimated Lipid Nanoparticles Market Size (2023E) | US$ 877.8 million |
| Projected Lipid Nanoparticles Market Size (2033F) | US$ 3.3 billion |
| Value-based Lipid Nanoparticles Market CAGR (2023 to 2033) | 14.2% |
Lipid nanoparticles are expected to offer advantages such as improved skin penetration and controlled release of active ingredients. This is set to result in better performance and efficacy of cosmetic and personal care products. Cosmetic products made of lipid nanoparticles are expected to be in high demand as these work as an anti-aging treatment and shield against radiation damage to the skin.
Due to their antioxidant properties, cosmetics companies are using naturally occurring antioxidants such as carotenoids, retinoids, and tocopherols as skincare and therapeutic active ingredients in their products. An anti-inflammatory and irritation-fighting cosmetic formulation based on lipid nanoparticles and antioxidants holds significant potential for treating skin conditions such as atopic dermatitis and psoriasis.
Over free drug delivery, nanoparticle-based drug delivery is expected to improve efficacy and drug accumulation. Circulation, half-life, surface features, size, and the level of angiogenesis are all factors that are anticipated to influence the distribution of nanoparticles within tumor tissues.
The evolution of new laws, extra funding possibilities, and increased public-private collaborations are set to drive the expansion of creative, collaborative research prospects in liposomal medicinal formulations. There has been a significant shift in emphasis toward creating lipid-based excipients that are dispersible, flexible, and multi-functional. In the forecast period, the demand for these excipients and oral formulations is projected to be driven by the constant focus on unmet medical needs in lipid-based medications.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global lipid nanoparticles market held around 16.0% of the total US$ 4.9 billion of the global pharmaceutical lipid market in 2022. Nanoparticles have qualitatively different physicochemical properties than micron-sized particles, which can result in altered body distribution, penetration of the blood-brain barrier, and activation of blood coagulation pathways.
The risks posed by utilizing nanoparticles for medicine administration go beyond the risks posed by chemicals in traditional delivery matrices. For nanoparticles, knowledge of particle toxicity as derived via inhalation toxicity demonstrates how to evaluate the possible risks of nanoparticles.
Both customized medicine and nanomedicine are relatively recent concepts in medical practice. Nanomedicine is expected to be integrated into diagnostic and therapeutic instruments to address a wide range of medical diseases.
Personalized medicine, or precision medicine, is also anticipated to individualize/customize therapeutic management based on the patient's characteristics to overcome blanket treatment. It is projected to be only effective in a subset of patients, leaving others with either ineffective treatment or treatment that causes significant toxicity. Due to these factors, the global lipid nanoparticles market is projected to surge at a CAGR of 14.2% in the forecast period.
During the historical period, the pharmaceutical industry witnessed rapid growth in outsourcing pharmaceutical services. This expansion is mainly attributed to the rising demand for pharmaceutical lipids.
Due to technological and regular operational hurdles, a growing number of pharmaceutical firms are opting to outsource their respective lipid manufacturing operations to specialist service providers. Several advantages of using CDMOs for lipid production are anticipated to push their demand.
For instance, contracting a supplier for medical-grade lipids would allow sponsors to take advantage of new technology (available through the service provider), access higher capacities, and gain better operational flexibility. There are now several contract manufacturers and technology suppliers claiming to be able to produce lipid-based drug delivery systems (such as liposomes/lipid nanoparticles) and lipid excipients.
| Attributes | Key Factors |
|---|---|
| Lipid Nanoparticles Market Trends |
|
| Growth Hindrances |
|
| Upcoming Opportunities |
|
Principal Consultant
In the table below, the CAGRs of the top 6 countries are given for the review period 2023 to 2033. The United Kingdom and India are expected to remain dominant by exhibiting CAGRs of 19.9% and 18.6%, respectively. Japan, China, and the United States are further anticipated to follow with CAGRs of 17.7%, 15.6%, and 15.2%, respectively.
| Countries | Value CAGR |
|---|---|
| United States | 15.2% |
| Germany | 14.5% |
| United Kingdom | 19.9% |
| Japan | 17.7% |
| China | 15.6% |
| India | 18.6% |
The United States occupied a 29.0% value share in the global lipid nanoparticles market in 2022, and expenditure on lipid nanoparticles in 2022 was US$ 228.4 million. The country boasts a thriving biotechnology and pharmaceutical sector.
It is also the home to several key pharmaceutical companies, start-ups, and research institutions. This ecosystem fosters innovation in drug delivery technologies, including lipid nanoparticles.
The United States invests heavily in research and development from the public and private sectors. Government agencies such as the National Institutes of Health (NIH) and the National Science Foundation (NSF) provide substantial funding for research in areas, including drug delivery systems, which involve lipid nanoparticles. The United States' high incidence of chronic diseases and emergency visits positions it as a critical market for lipid nanoparticles.
Germany held a 20.2% value share in Europe in 2022, and expenditure on lipid nanoparticles in the same year was US$ 33.9 million. Thanks to Germany's strategic location in the continent, companies have access to a sizable and diverse Europe market. This benefits clinical trials and commercialization efforts, enabling businesses to reach a broad customer base.
Germany also benefits from an administrative system that permits streamlined approvals in the European Union (EU) as a member of the EU. Lipid nanoparticle-based medications and therapies are heavily regulated and approved by the European Medicines Agency (EMA). Similar to the United States, Germany provides strong intellectual property protection, encouraging businesses to spend on research and development and safeguard their ideas.
In 2022, Japan held a dominant revenue in the East Asia market and contributed around US$ 49.1 million. A solid and innovative pharmaceutical sector exists in Japan. Japan-based businesses have a proven track record of creating and producing pharmaceutical products, which can include lipid nanoparticles for medication delivery.
Japan-based colleges and research facilities are famous for their superior scientific capabilities. Lipid nanoparticle technology is set to improve due to partnerships between academic institutions and private sector businesses in Japan.
Japan also has a robust regulatory system in place for drugs and medical equipment. This regulatory experience can aid the development and approval of medicines and therapies based on lipid nanoparticles.
China’s lipid nanoparticles market is poised to exhibit a CAGR of 15.6% during the assessment period. The country has a burgeoning nanotechnology and medication delivery systems research and development scene. Biotechnology businesses, research organizations, and universities in China are conducting LNP research.
China's government has shown a persistent dedication to advancing life sciences and biotechnology, particularly nanotechnology. Several grant schemes and incentives are available to facilitate research in these fields.
The healthcare industry in China is vast and developing quickly, and there is an increasing need for cutting-edge medication delivery methods. This makes the environment ideal for LNP's growth and commercialization.
China has also demonstrated interest in mRNA vaccine technology, which generally employs lipid nanoparticles for delivery, and has actively participated in vaccine expansion. This encounter can have inspired more LNP research and knowledge.
China is an essential player in the worldwide clinical trials landscape. Several multinational pharmaceutical firms are conducting clinical trials in China, allowing LNPs to be tested on different patient groups.
The table below signifies leading sub-categories under application and product categories in the lipid nanoparticles market. Therapeutics are expected to dominate the market for lipid nanoparticles by exhibiting a 16.6% CAGR in the evaluation period. Under the product category, the solid lipid nanoparticles segment is projected to lead the global market at a 15.3% CAGR.
| Segment | Value CAGR |
|---|---|
| Therapeutics (Application) | 16.6% |
| Pharmaceutical and Biotechnology Companies (End-use) | 16.3% |
| Solid Lipid Nanoparticles (Product) | 15.3% |
By type, solid lipid nanoparticles (SLNs) covered 64.8% of market shares in the world in 2022. The segment is predicted to expand rapidly between 2023 and 2033 in the nanostructured lipid carrier business.
Compared to other lipid-based delivery methods, solid lipid nanoparticles are set to be less prone to problems such as drug leakage, aggregation, or degradation over time. This is mainly because of their intrinsic solid-state stability.
With extensive drug-loading capabilities, SLNs can encapsulate a range of hydrophobic and hydrophilic medicines. The ability to administer a wide range of medicinal chemicals depends on this adaptability, which would spur demand.
The value of therapeutics in the lipid nanoparticles market was US$ 464.9 million, representing a 58.9% share in 2022. Lipid nanoparticles, such as solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), are particularly effective at encapsulating a variety of therapeutic agents.
Their ability to encapsulate agents, such as hydrophobic and hydrophilic pharmaceuticals, peptides, nucleic acids (RNA and DNA), and small molecules is anticipated to aid demand. Improved medication solubility and bioavailability are also projected to push demand.
Lipid nanoparticles are expected to provide encapsulated medications with protection from deterioration, especially for medications vulnerable to enzymatic or chemical disintegration. The shelf life of medicinal formulations is increased as a result, which would spur sales.
The pharmaceutical and biotechnology companies have a considerable presence in the lipid nanoparticles market, accounting for 45.2% of the share in terms of end users in 2022. The segment will likely exhibit a high CAGR of 16.3% over the forecast period. These businesses are primarily concerned with creating novel medications and treatments.
Leading pharmaceutical and biotechnology companies are expected to develop new nanoparticles to provide a flexible platform for delivering several pharmacological substances, including peptides, nucleic acids, small molecules, and biologics. These companies are projected to increase the solubility, stability, and bioavailability of novel substances by utilizing lipid nanoparticles, which will result in more potent medicines.
Pharmaceutical and biotechnology companies can also create medicines directly targeting diseased cells or tissues while reducing systemic adverse effects. They are expected to do so by engineering lipid nanoparticles to enable targeted drug delivery. The advancement of precision medicine and individualized treatments depends heavily on this targeted strategy.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Advancements and partnerships among healthcare providers, research institutes, and tech enterprises would gradually foster cutting-edge innovation. Collaborative efforts among manufacturers are set to boost market expansion and diversify applications.
The lipid nanoparticles market is highly competitive. Key manufacturers constantly innovate and develop novel yet economical product lines to increase their consumer base in emerging regions. Establishing new manufacturing sites is the primary emphasis of key firms seeking to expand their geographic reach.
For instance,
| Attribute | Details |
|---|---|
| Estimated Lipid Nanoparticles Market Revenue (2023) | US$ 877.8 million |
| Projected Lipid Nanoparticles Market Revenue (2033) | US$ 3.3 billion |
| Value-based CAGR (2023 to 2033) | 14.2% |
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | US$ million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East and Africa |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, United Kingdom, Spain, BENELUX, Russia, China, Japan, South Korea, India, Indonesia, Thailand, Malaysia, Australia, New Zealand, GCC countries, Türkiye, Northern Africa and South Africa. |
| Key Market Segments Covered | Type, Application, End User, Region |
| Key Companies Profiled | Abbott; NOF Corporation; Merck KGaA (Exelead); Evonik Industries AG; Gattefossé; Danaher Corporation (Precision NanoSystems); IOI Oleo GmbH; Genevant Sciences; Croda International Plc (Avanti Polar Lipids, Inc.); Lipoid GmbH; CordenPharma International; Cayman Chemical; ABITEC Corporation |
| Report Coverage | Market Forecast, Competition Intelligence, Market Dynamics and Challenges, Strategic Growth Initiatives |
The market was worth US$ 789.0 million in 2022.
The market is estimated to reach around US$ 877.8 million by 2023.
The global market is expected to reach US$ 3.3 billion by the end of 2033.
The market grew at a CAGR of 9.5% between 2018 and 2022.
The United States contributed around US$ 228.4 million in 2022.
Germany held around 20.2% of the market value share in 2022.
Japan is set to witness a CAGR of 17.7% from 2023 to 2033.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Innovation Trends
4. Value-Added Insights
4.1. Product Usage/Adoption Analysis
4.2. Regulatory Scenario
4.3. PESTEL Analysis
4.4. Porters Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global Healthcare Expenditure
5.1.2. Global Life Expectancy Outlook
5.1.3. Research and Development funding By Region
5.1.4. Research and Development funding By Country
5.2. Forecast Factors - Relevance & Impact
5.2.1. Increasing Application of in Drug Delivery
5.2.2. Increased Number of Product Launches
5.2.3. Increasing Demand for (LNPs) By Pharmaceutical Companies
5.2.4. Rising Healthcare Expenditure
5.2.5. Growing Demand for Sustained-release Formulations
5.2.6. Historic Growth of Key Companies
5.2.7. Pharmaceutical and Biomedical Applications
5.2.8. Consumer Preferences
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Global Market Demand (in Value or Size in US$ million) Analysis 2018 to 2022 and Forecast, 2023 to 2033
6.1. Historical Market Value (US$ million) Analysis, 2018 to 2022
6.2. Current and Future Market Value (US$ million) Projections, 2023 to 2033
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Absolute $ Opportunity Analysis
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ million) Analysis By Type, 2018 to 2022
7.3. Current and Future Market Size (US$ million) Analysis and Forecast By Type, 2023 to 2033
7.3.1. Solid Lipid Nanoparticles
7.3.2. Nanostructured Lipid Carriers
7.3.3. Others
7.4. Market Attractiveness Analysis By Type
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ million) By Application, 2018 to 2022
8.3. Current and Future Market Size (US$ million) Analysis and Forecast By Application, 2023 to 2033
8.3.1. Therapeutics
8.3.2. Research
8.4. Market Attractiveness Analysis By Application
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ million) By End User, 2018 to 2022
9.3. Current and Future Market Size (US$ million) Analysis and Forecast By End User, 2023 to 2033
9.3.1. Pharmaceutical & Biotechnology Companies
9.3.2. Academics & Research Centers
9.3.3. Others
9.4. Market Attractiveness Analysis By End User
10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ million) Trend Analysis by Region, 2018 to 2022
10.3. Current and Future Market Size (US$ million) Analysis and Forecast by Region, 2023 to 2033
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. East Asia
10.3.5. South Asia
10.3.6. Oceania
10.3.7. Middle East and Africa
10.4. Market Attractiveness Analysis by Region
11. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
11.1. Introduction
11.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2018 to 2022
11.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
11.3.1. By Country
11.3.1.1. United States
11.3.1.2. Canada
11.3.2. By Type
11.3.3. By Application
11.3.4. By End User
11.4. Market Attractiveness Analysis
11.4.1. By Country
11.4.2. By Type
11.4.3. By Application
11.4.4. By End User
11.5. Country-Wise Analysis
11.5.1. United States Market Analysis
11.5.1.1. Introduction
11.5.1.2. Market Analysis and Forecast by Market Taxonomy
11.5.1.2.1. By Type
11.5.1.2.2. By Application
11.5.1.2.3. By End User
11.5.2. Canada Market Analysis
11.5.2.1. Introduction
11.5.2.2. Market Analysis and Forecast by Market Taxonomy
11.5.2.2.1. By Type
11.5.2.2.2. By Application
11.5.2.2.3. By End User
12. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
12.1. Introduction
12.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2018 to 2022
12.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
12.3.1. By Country
12.3.1.1. Brazil
12.3.1.2. Mexico
12.3.1.3. Argentina
12.3.1.4. Rest of Latin America
12.3.2. By Type
12.3.3. By Application
12.3.4. By End User
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Type
12.4.3. By Application
12.4.4. By End User
12.5. Country-Wise Analysis
12.5.1. Brazil Market Analysis
12.5.1.1. Introduction
12.5.1.2. Market Analysis and Forecast by Market Taxonomy
12.5.1.2.1. By Type
12.5.1.2.2. By Application
12.5.1.2.3. By End User
12.5.1.2.4. By Route of Administration
12.5.1.2.5. By End User
12.5.2. Mexico Market Analysis
12.5.2.1. Introduction
12.5.2.2. Market Analysis and Forecast by Market Taxonomy
12.5.2.2.1. By Type
12.5.2.2.2. By Application
12.5.2.2.3. By End User
12.5.2.2.4. By Route of Administration
12.5.2.2.5. By End User
12.5.3. Argentina Market Analysis
12.5.3.1. Introduction
12.5.3.2. Market Analysis and Forecast by Market Taxonomy
12.5.3.2.1. By Type
12.5.3.2.2. By Application
12.5.3.2.3. By End User
12.5.3.2.4. By Route of Administration
12.5.3.2.5. By End User
13. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033
13.1. Introduction
13.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2018 to 2022
13.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
13.3.1. By Country
13.3.1.1. Germany
13.3.1.2. Italy
13.3.1.3. France
13.3.1.4. United Kingdom
13.3.1.5. Spain
13.3.1.6. BENELUX
13.3.1.7. Nordic Countries
13.3.1.8. Russia
13.3.1.9. Rest of Europe
13.3.2. By Type
13.3.3. By Application
13.3.4. By End User
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Type
13.4.3. By Application
13.4.4. By End User
13.5. Country-Wise Analysis
13.5.1. Germany Market Analysis
13.5.1.1. Introduction
13.5.1.2. Market Analysis and Forecast by Market Taxonomy
13.5.1.2.1. By Type
13.5.1.2.2. By Application
13.5.1.2.3. By End User
13.5.2. Italy Market Analysis
13.5.2.1. Introduction
13.5.2.2. Market Analysis and Forecast by Market Taxonomy
13.5.2.2.1. By Type
13.5.2.2.2. By Application
13.5.2.2.3. By End User
13.5.3. France Market Analysis
13.5.3.1. Introduction
13.5.3.2. Market Analysis and Forecast by Market Taxonomy
13.5.3.2.1. By Type
13.5.3.2.2. By Application
13.5.3.2.3. By End User
13.5.4. United Kingdom Republic Market Analysis
13.5.4.1. Introduction
13.5.4.2. Market Analysis and Forecast by Market Taxonomy
13.5.4.2.1. By Type
13.5.4.2.2. By Application
13.5.4.2.3. By End User
13.5.5. Spain Republic Market Analysis
13.5.5.1. Introduction
13.5.5.2. Market Analysis and Forecast by Market Taxonomy
13.5.5.2.1. By Type
13.5.5.2.2. By Application
13.5.5.2.3. By End User
13.5.6. BENELUX Market Analysis
13.5.6.1. Introduction
13.5.6.2. Market Analysis and Forecast by Market Taxonomy
13.5.6.2.1. By Type
13.5.6.2.2. By Application
13.5.6.2.3. By End User
13.5.7. Nordic Countries Market Analysis
13.5.7.1. Introduction
13.5.7.2. Market Analysis and Forecast by Market Taxonomy
13.5.7.2.1. By Type
13.5.7.2.2. By Application
13.5.7.2.3. By End User
13.5.8. Russia Market Analysis
13.5.8.1. Introduction
13.5.8.2. Market Analysis and Forecast by Market Taxonomy
13.5.8.2.1. By Type
13.5.8.2.2. By Application
13.5.8.2.3. By End User
13.5.9. No
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2018 to 2022
14.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. China
14.3.1.2. Japan
14.3.1.3. South Korea
14.3.2. By Type
14.3.3. By Application
14.3.4. By End User
14.3.5. By Route of Administration
14.3.6. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Type
14.4.3. By Application
14.4.4. By End User
14.4.5. By Route of Administration
14.4.6. By End User
14.5. Country-Wise Analysis
14.5.1. China Market Analysis
14.5.1.1. Introduction
14.5.1.2. Market Analysis and Forecast by Market Taxonomy
14.5.1.2.1. By Type
14.5.1.2.2. By Application
14.5.1.2.3. By End User
14.5.2. Japan Market Analysis
14.5.2.1. Introduction
14.5.2.2. Market Analysis and Forecast by Market Taxonomy
14.5.2.2.1. By Type
14.5.2.2.2. By Application
14.5.2.2.3. By End User
14.5.3. South Korea Market Analysis
14.5.3.1. Introduction
14.5.3.2. Market Analysis and Forecast by Market Taxonomy
14.5.3.2.1. By Type
14.5.3.2.2. By Application
14.5.3.2.3. By End User
15. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2018 to 2022
15.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. India
15.3.1.2. Indonesia
15.3.1.3. Malaysia
15.3.1.4. Thailand
15.3.1.5. Rest of South Asia
15.3.2. By Type
15.3.3. By Application
15.3.4. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Type
15.4.3. By Application
15.4.4. By End User
15.5. Country-Wise Analysis
15.5.1. India Market Analysis
15.5.1.1. Introduction
15.5.1.2. Market Analysis and Forecast by Market Taxonomy
15.5.1.2.1. By Type
15.5.1.2.2. By Application
15.5.1.2.3. By End User
15.5.1.2.4. By Route of Administration
15.5.1.2.5. By End User
15.5.2. Indonesia Market Analysis
15.5.2.1. Introduction
15.5.2.2. Market Analysis and Forecast by Market Taxonomy
15.5.2.2.1. By Type
15.5.2.2.2. By Application
15.5.2.2.3. By End User
15.5.2.2.4. By Route of Administration
15.5.2.2.5. By End User
15.5.3. Malaysia Market Analysis
15.5.3.1. Introduction
15.5.3.2. Market Analysis and Forecast by Market Taxonomy
15.5.3.2.1. By Type
15.5.3.2.2. By Application
15.5.3.2.3. By End User
15.5.3.2.4. By Route of Administration
15.5.3.2.5. By End User
15.5.4. Thailand Market Analysis
15.5.4.1. Introduction
15.5.4.2. Market Analysis and Forecast by Market Taxonomy
15.5.4.2.1. By Type
15.5.4.2.2. By Application
15.5.4.2.3. By End User
15.5.4.2.4. By Route of Administration
15.5.4.2.5. By End User
16. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2018 to 2022
16.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. Australia
16.3.1.2. New Zealand
16.3.2. By Type
16.3.3. By Application
16.3.4. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Type
16.4.3. By Application
16.4.4. By End User
16.5. Country-Wise Analysis
16.5.1. Australia Market Analysis
16.5.1.1. Introduction
16.5.1.2. Market Analysis and Forecast by Market Taxonomy
16.5.1.2.1. By Type
16.5.1.2.2. By Application
16.5.1.2.3. By End User
16.5.2. New Zealand Market Analysis
16.5.2.1. Introduction
16.5.2.2. Market Analysis and Forecast by Market Taxonomy
16.5.2.2.1. By Type
16.5.2.2.2. By Application
16.5.2.2.3. By End User
17. Middle East & Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2018 to 2022
17.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. GCC Countries
17.3.1.2. Türkiye
17.3.1.3. South Africa
17.3.1.4. Rest of Middle East and Africa
17.3.2. By Type
17.3.3. By Application
17.3.4. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Type
17.4.3. By Application
17.4.4. By End User
17.5. Country-Wise Analysis
17.5.1. GCC Countries Market Analysis
17.5.1.1. Introduction
17.5.1.2. Market Analysis and Forecast by Market Taxonomy
17.5.1.2.1. By Type
17.5.1.2.2. By Application
17.5.1.2.3. By End User
17.5.2. Turkey Market Analysis
17.5.2.1. Introduction
17.5.2.2. Market Analysis and Forecast by Market Taxonomy
17.5.2.2.1. By Type
17.5.2.2.2. By Application
17.5.2.2.3. By End User
17.5.3. South Africa Market Analysis
17.5.3.1. Introduction
17.5.3.2. Market Analysis and Forecast by Market Taxonomy
17.5.3.2.1. By Type
17.5.3.2.2. By Application
17.5.3.2.3. By End User
18. Market Structure Analysis
18.1. Market Analysis by Tier of Companies
18.2. Market Share Analysis of Top Players
19. Competition Analysis
19.1. Competition Dashboard
19.2. Competition Benchmarking
19.3. Competition Deep Dive
19.3.1. NOF corporation
19.3.1.1. Overview
19.3.1.2. Key Financials
19.3.1.3. SWOT Analysis
19.3.1.4. Key Developments
19.3.1.5. Sales Footprint
19.3.1.6. Strategy Overview
19.3.1.6.1. Marketing Strategy
19.3.1.6.2. Channel Strategy
19.3.2. Merck KGaA (Exelead)
19.3.2.1. Overview
19.3.2.2. Key Financials
19.3.2.3. SWOT Analysis
19.3.2.4. Key Developments
19.3.2.5. Sales Footprint
19.3.2.6. Strategy Overview
19.3.2.6.1. Marketing Strategy
19.3.2.6.2. Channel Strategy
19.3.3. Evonik Industries AG
19.3.3.1. Overview
19.3.3.2. Key Financials
19.3.3.3. SWOT Analysis
19.3.3.4. Key Developments
19.3.3.5. Sales Footprint
19.3.3.6. Strategy Overview
19.3.3.6.1. Marketing Strategy
19.3.3.6.2. Channel Strategy
19.3.4. Gattefossé
19.3.4.1. Overview
19.3.4.2. Key Financials
19.3.4.3. SWOT Analysis
19.3.4.4. Key Developments
19.3.4.5. Sales Footprint
19.3.4.6. Strategy Overview
19.3.4.6.1. Marketing Strategy
19.3.4.6.2. Channel Strategy
19.3.5. Danaher Corporation (Precision NanoSystems)
19.3.5.1. Overview
19.3.5.2. Key Financials
19.3.5.3. SWOT Analysis
19.3.5.4. Key Developments
19.3.5.5. Sales Footprint
19.3.5.6. Strategy Overview
19.3.5.6.1. Marketing Strategy
19.3.5.6.2. Channel Strategy
19.3.6. IOI Oleo GmbH
19.3.6.1. Overview
19.3.6.2. Key Financials
19.3.6.3. SWOT Analysis
19.3.6.4. Key Developments
19.3.6.5. Sales Footprint
19.3.6.6. Strategy Overview
19.3.6.6.1. Marketing Strategy
19.3.6.6.2. Channel Strategy
19.3.7. Genevant Sciences
19.3.7.1. Overview
19.3.7.2. Key Financials
19.3.7.3. SWOT Analysis
19.3.7.4. Key Developments
19.3.7.5. Sales Footprint
19.3.7.6. Strategy Overview
19.3.7.6.1. Marketing Strategy
19.3.7.6.2. Channel Strategy
19.3.8. Croda International Plc (Avanti Polar Lipids, Inc.)
19.3.8.1. Overview
19.3.8.2. Key Financials
19.3.8.3. SWOT Analysis
19.3.8.4. Key Developments
19.3.8.5. Sales Footprint
19.3.8.6. Strategy Overview
19.3.8.6.1. Marketing Strategy
19.3.8.6.2. Channel Strategy
19.3.9. Lipoid GmbH
19.3.9.1. Overview
19.3.9.2. Key Financials
19.3.9.3. SWOT Analysis
19.3.9.4. Key Developments
19.3.9.5. Sales Footprint
19.3.9.6. Strategy Overview
19.3.9.6.1. Marketing Strategy
19.3.9.6.2. Channel Strategy
19.3.10. CordenPharma International
19.3.10.1. Overview
19.3.10.2. Key Financials
19.3.10.3. SWOT Analysis
19.3.10.4. Key Developments
19.3.10.5. Sales Footprint
19.3.10.6. Strategy Overview
19.3.10.6.1. Marketing Strategy
19.3.10.6.2. Channel Strategy
19.3.11. Cayman Chemical
19.3.11.1. Overview
19.3.11.2. Key Financials
19.3.11.3. SWOT Analysis
19.3.11.4. Key Developments
19.3.11.5. Sales Footprint
19.3.11.6. Strategy Overview
19.3.11.6.1. Marketing Strategy
19.3.11.6.2. Channel Strategy
19.3.12. ABITEC Corporation
19.3.12.1. Overview
19.3.12.2. Key Financials
19.3.12.3. SWOT Analysis
19.3.12.4. Key Developments
19.3.12.5. Sales Footprint
19.3.12.6. Strategy Overview
19.3.12.6.1. Marketing Strategy
19.3.12.6.2. Channel Strategy
20. Assumptions and Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports
Lipid Nanoparticles Market
